Trypanosoma cruzi, the protozoan pathogen that causes Chagas' disease, can be found in the blood of infected individuals for their entire life span. This presents a serious challenge in safeguarding blood products. Transmission of T. cruzi from blood products is a frequent occurrence in Latin America, where Chagas' disease is endemic. This study was designed to determine whether T. cruzi could be inactivated in human platelet concentrates and plasma by a photochemical treatment process with long-wavelength UV A light (UVA, 320 to 400 nm) plus the psoralen amotosalen HCl (Cerus Corporation). Units of platelet concentrates (300 ml) and plasma (300 ml) were intentionally contaminated with approximately 10 6 T. cruzi trypomastigotes, the T. cruzi form found in the bloodstream, per ml. The viability of T. cruzi after photochemical inactivation was determined by their ability to replicate in 3T3 fibroblasts. Controls, including treatment with 150 M amotosalen or 3 J/cm 2 UVA alone, did not lead to reduction of the viability of T. cruzi in plasma or platelet concentrates. However, treatment with 150 M amotosalen plus 3 J/cm 2 UVA inactivated T. cruzi to undetectable levels in plasma and platelet concentrates. This represented a >5.4-log reduction of T. cruzi in platelet concentrates and >5.0-log reduction of T. cruzi in plasma. We conclude that the amotosalen plus UVA photochemical inactivation technology is effective in inactivating high levels of protozoan pathogens, such as T. cruzi, in platelet concentrates and plasma, as has been previously shown for numerous viruses and bacteria.
Trypanosoma cruzi is a vector-borne protozoan pathogen that causes Chagas' disease, which is responsible for serious morbidity and mortality. Once infection is established, therapy for T. cruzi is difficult; available drugs are toxic, and a minimum of 90 days of treatment is required to achieve cure. Even under optimal treatment conditions, a cure is achieved in less than 50% of cases (8) . The World Health Organization estimates that 18 to 20 million people in Latin America are infected with T. cruzi (27) . T. cruzi establishes a life-long blood and tissue infection (3) . Because of this, T. cruzi remains a serious threat to the public blood supply (26a) .
T. cruzi infection by blood transfusion frequently occurs in areas of Latin America where blood products are not screened for T. cruzi antibodies (21; Wendel et al., abstr. 271, 1992) . The risk of acquiring T. cruzi infection from a blood product that is seropositive is estimated to be between 12 and 25% (1) . The World Health Organization and Pan American Health Organization have aggressively promoted screening all blood products for T. cruzi by serology; however, logistical difficulties have interfered with universal implementation in Latin America (21) . To date, United States blood banks have not implemented screening for T. cruzi serologies. The immigration of Latin Americans into the United States ensures that there is a risk of transfusion infection with T. cruzi (6, (10) (11) (12) 22) . Indeed, at least six documented transfusion-associated T. cruzi infections have occurred in the United States and Canada (5, 7, 24) , and probably many more undocumented transfusion-associated infections have occurred.
Long-wavelength UV A light (UVA, 320 to 400 nm) plus psoralen (amotosalen HCl) photochemical treatment (Cerus Corporation) has been shown to be effective in inactivation of high levels of a broad spectrum of bacteria and viruses in therapeutic units of human plasma and platelet concentrates (9, 14) . Amotosalen is a nucleic acid-targeting reagent that intercalates and forms cross-links into the double helix or single-strand hairpin loops of nucleic acids (DNA and RNA). When illuminated with UVA, it forms covalent monoadducts with pyrimidine bases on a single strand of nucleic acid. Additional illumination causes the monoadduct to link with a second pyrimidine base, producing an inter-or intrastrand crosslink and thus disabling the transcription and replication processes. The technology is simple to implement and could eventually substitute for extensive testing of blood products for viral and bacterial contamination.
Amotosalen plus UVA treatment of platelets does not alter platelet function in in vitro tests, including: platelet count, morphology, ATP secretion, hypotonic shock response, platelet shape change, platelet aggregation, and platelet activation by p-selectin expression (13, 14) . The amotosalen plus UVA photoinactivation technology has received a CE mark (a symbol that shows that the goods meet the European Union's product safety standards) in Europe, and the regulatory approval process in the United States has been initiated. This technology has not previously been tested for inactivation of blood-borne trypanosomatid infections, such as T. cruzi, Trypanosoma brucei spp. (agents of African sleeping sickness), or Leishmania spp.
We report here that UVA plus amotosalen treatment of human platelet concentrates and plasma is extremely effective in inactivating T. cruzi and thus should protect patients from T. cruzi infection transmitted by blood products.
MATERIALS AND METHODS
T. cruzi Tulahuen strain was used for these experiments (19) . T. cruzi trypomastigotes used for these experiments were grown on BALB/c mouse NIH clone A31 3T3 fibroblast cells (CCL 163, American Type Culture Collection) in RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum, L-glutamine, penicillin, and streptomycin (culture medium). Trypomastigotes were collected from tissue culture supernatant by centrifugation, counted with a hemacytometer, and resuspended in normal saline.
The process of photochemical inactivation with amotosalen plus UVA (Helinx Technology) has been developed by Cerus Corporation, Concord, Calif. Approximately 3 ϫ 10 9 (range, 2.1 ϫ 10 8 to 1.2 ϫ 10 10 ) T. cruzi trypomastigotes in 6 ml of normal saline were added to either two pooled, ABO-matched single-donor units of platelet concentrates (approximately 570 ml) or approximately 570 ml of pooled random donor plasma. Platelet concentrates were collected on an Amicus Cell Separator at the Puget Sound Blood Center (Seattle, Wash.) and suspended in approximately 65% normal saline and 35% autologous plasma. Plasma was obtained as fresh frozen plasma, collected in acid citrate dextrose solution, from the Sacramento Blood Center (Sacramento, Calif.). An aliquot of the saline suspension was diluted at the same ratio in culture medium to serve as a control for the effects of platelet concentrates or plasma alone on the viability of the organisms.
After mixing, the platelet concentrates or plasma was divided into two 285-ml aliquots in PL 2410 illumination containers (Baxter Healthcare Corporation). One container was used as a control without amotosalen, and 15 ml of sterile saline, in lieu of amotosalen, was added to this container. The second (test) container was sterilely connected to one line of a pouch containing 15 ml of 3 mM amotosalen in saline. The other line of the amotosalen pouch was sterilely connected to an empty 1-liter PL 2410 illumination container, forming a chain. The infected platelet concentrate or plasma mixture was passed back and forth through the amotosalen container three times to ensure adequate mixing, ending in a PL 2410 illumination container (final amotosalen concentration was approximately 150 M).
Samples were taken from both the control container and the amotosalentreated container immediately after mixing and after each UVA illumination (1, 2, and 3 J/cm 2 ). The plasma or platelet concentrates spiked with T. cruzi were illuminated in serial 1-J/cm 2 increments for a total UVA treatment of 1, 2, or 3 J/cm 2 . Treatment was performed on a UVA light apparatus that provided 320-to 400-nm long-wavelength UVA light above and below the containers while shaking them continuously (Fenwal model FX-1019; Baxter Healthcare Corporation). The control units were not actually illuminated but were sampled in parallel with the test units to demonstrate stability of the organism in the blood component. After the 3-J/cm 2 treatment sample was taken, each control unit received a single 3-J/cm 2 UVA treatment, which served as a control for the effect of UVA without amotosalen. As an additional control, plasma samples containing T. cruzi were removed from the control unit and exposed to a 137 cesium source delivering 440 cGy/min of gamma irradiation, for a total of 2,500 cGy.
To assay the viability of trypomastigotes, samples were diluted in culture medium, either 1:3 or serially 1:10, through 10 Ϫ7 . One tenth milliliter of each dilution was transferred to each of five replicate wells of a 96-well tissue culture plate seeded 18 h previously with 1,000 3T3 cells in 0.1 ml of culture medium. An inverted microscope was used to examine the microtiter plates for the presence of live trypomastigotes every 3 to 4 days. Wells were scored as positive for growth if T. cruzi trypomastigotes were present any time during the 7 to 28 days following plating.
This study consisted of four replicate independent inactivation experiments in platelet concentrates and an additional four replicates in plasma. For each replicate, the method developed by Reed and Muench was used to estimate the 50% tissue culture infectious dose (TCID 50 , the dilution at which 50% of the wells are infected) from the numbers of positive and negative wells at each dilution (18) . The level of T. cruzi inactivation was determined by subtracting the TCID 50 after illumination from the TCID 50 of the control unit sampled concurrently. Results for the study of each blood component were calculated as the mean and standard deviation of the four replicate experiments.
RESULTS
T. cruzi trypomastigotes were spiked into human platelet concentrates or plasma to titers of approximately 10 6 /ml. Half
FIG. 1. T. cruzi in medium only
(open bar) and after 3-J/cm 2 UVA only (shaded bar). After the untreated control unit had been sampled at all illumination points, it was exposed to a single 3-J/cm 2 UVA illumination (open squares). These samples were not exposed to UVA, but the unit was sampled at the indicated time points in parallel with the treated test unit (open circles). Arrows indicate that the T. cruzi titer was below the level of detection. Platelet units were pooled, inoculated with T. cruzi, and then split to generate the test and control units. 
a Without amotosalen or UVA. Controls were not actually exposed to the UVA indicated but were sampled at these points in parallel with the illuminated test samples.
b In one of the four replicates, one sample yielded a positive well in an unexpected location. This was likely the product of cross-contamination from an adjacent control well with a high titer of T. cruzi.
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on June 21, 2017 by guest http://aac.asm.org/ of the material was treated with UVA plus the psoralen amotosalen, and half was reserved for controls. Tables 1 and 2 contain the results, expressed as log 10 TCID 50 of trypomastigotes in the various samples, and Fig. 1 and 2 graphically depict the log reduction of viable organisms. Exposure of T. cruzi to human platelet concentrates or plasma alone (control samples) had little effect on viability of T. cruzi over the course of the experiment, as evidenced by the mean titer of the control samples at the various illumination points, which varied by less than 0.5 log. The viability of T. cruzi was not significantly affected by a 3-J/cm 2 UVA treatment in the absence of amotosalen (control samples with 3-J/cm 2 UVA illumination) or by amotosalen in the absence of UVA (0-J/cm 2 test samples). In both cases, the mean T. cruzi titer varied by less than 0.5 log from the titer of organisms in culture medium alone.
Treatment of T. cruzi with 150 M amotosalen and as little as 1 J/cm 2 of UVA led to complete abrogation of the ability of T. cruzi to infect 3T3 fibroblasts. The limit of detection of Ͻ1.3 log 10 TCID 50 /ml (plasma) or Ͻ0.8 log 10 TCID 50 /ml (platelets) was governed by the amount of plasma or platelet concentrates that could be plated without interfering with the viability of the 3T3 fibroblasts. No T. cruzi were detected in any of the samples treated with 150 M amotosalen and 1, 2, or 3 J/cm 2 UVA illumination. The initial titer of T. cruzi was 6.1 Ϯ 0.5 log 10 TCID 50 /ml in plasma and 6.1 Ϯ 0.4 log 10 TCID 50 /ml in platelet concentrates (Table 1 and Fig. 1 ).
Photochemical treatment with amotosalen and UVA resulted in inactivation of Ͼ5.0 Ϯ 0.6 logs of T. cruzi in plasma and inactivation of Ն5.4 Ϯ 0.1 logs of T. cruzi in platelet concentrates (Table 2 and Fig. 2) . In one replicate of the inactivation studies in platelet concentrates, a single infected well was found in an unexpected location in the dilution series for one sample. Based on the location of the well, it is most likely that the positive result was due to cross-contamination from an adjacent control well with a high titer of T. cruzi. However, because this cannot be demonstrated to be the case, the data were analyzed as if there truly were a single surviving organism in that one sample. This is why the titer in platelets after the 3-J/cm 2 UVA treatment is expressed as "greater than or equal to" instead of simply "greater than."
To compare photochemical treatment with amotosalen and UVA to an inactivation process currently used on blood products, two experiments were performed in which plasma spiked with T. cruzi was exposed to 2,500 cGy of ␥-irradiation, the dose of ␥-irradiation commonly used to inactivate leukocytes prior to transfusion. In sharp contrast to the UVA plus amotosalen treatment results, ␥-irradiation did not lead to a significant reduction of T. cruzi titers: 6.1 log 10 TCID 50 /ml after ␥-irradiation, compared to 6.2 Ϯ 0.5 log 10 TCID 50 /ml in the 0-J/cm 2 control (Table 2 and Fig. 2 ).
DISCUSSION
The UVA and amotosalen photochemical treatment method was assessed for its ability to inactivate blood-borne protozoan pathogens. This technology has been shown to inactivate many viral and bacterial pathogens (9, 14) , but inactivation of bloodborne parasites has not previously been evaluated. This UVA and amotosalen photochemical treatment is currently under   FIG. 2. T. cruzi in medium only (open bar), after gamma irradiation (stippled bar), and after 3-J/cm 2 UVA only (shaded bar). After the untreated control unit had been sampled at all illumination points, it was exposed to a single 3-J/cm 2 UVA illumination (open squares). These samples were not exposed to UVA, but the unit was sampled at the indicated time points in parallel with the treated test unit (open circles). Arrows indicate that the T. cruzi titer was below the level of detection. Platelet units were pooled, inoculated with T. cruzi, and then split to generate the test and control units. a Three replicates. The fourth replicate had a titer of Ͼ7. b Without amotosalen or UVA. Controls were not actually exposed to the UVA indicated but were sampled at these points in parallel with the illuminated test samples.
c Dose, 2,500 cGy, two replicates.
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review for approval in Europe, and the regulatory approval process in the United States has been initiated. To assess the efficacy of the photochemical treatment process for inactivation of trypanosomatid parasites, we chose T. cruzi because it poses a serious problem for transfusion medicine. Most seropositive individuals have lifelong circulating T. cruzi, usually without overt symptoms (3, 15, 25, 26a) . The risk of transmission from a seropositive blood product is estimated to be between 12 and 25% (26a). We tested the extracellular trypomastigote form of T. cruzi because they have the potential to contaminate plasma or platelet concentrates due to their small size and motility. The photochemical treatment process was able to inactivate T. cruzi to below the limit of detection in platelet concentrates and plasma, an average of Ͼ5.3 log 10 TCID 50 /ml and Ͼ4.9 log 10 TCID 50 /ml, respectively. Since the titer of T. cruzi in the blood of chronically infected individuals has been estimated to be only about 5 parasites/ml (3) , this technique appears to have sufficient capacity to inactivate all of the T. cruzi that would be found in a plasma or platelet unit from a chronically infected donor.
T cruzi inoculation of immunocompromised mice is another sensitive method to detect T. cruzi that could have been used in these studies. The 3T3 fibroblast tissue culture system used in this report can detect as few as 1 to 2 T. cruzi trypomastigotes per tissue culture well (unpublished data); this method is as sensitive as inoculation of immunocompromised mice. The failure of the 2,500-cGy dose of ␥-irradiation, which is commonly used to inactivate leukocytes in blood products, to significantly reduce T. cruzi titers indicates that current U.S. blood-processing procedures do not address potential contamination with this pathogen, underscoring the potential of the photochemical treatment process.
Though the exact numbers are not known, it is estimated that thousands of persons in Latin America are infected annually with T. cruzi as a result of transfusion with contaminated blood products (20) . Testing for anti-T. cruzi antibodies with at least two different serological tests and discarding positive units, can generally prevent T. cruzi infection from blood products (20) . Although serologic testing of blood products is performed in many areas of Latin America, there are still areas of Latin America where testing has not been implemented and transmission occurs unabated (20, 21) . The probability of receiving an infected blood unit in Latin America has been estimated to be as high as 1 in 10 in Bolivia and as low as 1 in 50,000 in the seven countries with universal serological testing (20) . In Bolivia, where the T. cruzi seropositive rate in blood donors is 25%, screening has not been implemented because there simply would not be enough blood available if all units seropositive for T. cruzi were discarded (20) . The amotosalen and UVA photochemical treatment process could inactivate T. cruzi in these blood products, rendering them safer for transfusion.
Testing of blood products for antibodies to T. cruzi has not been implemented in the United States and Canada. Estimates of the risk to the U.S. and Canadian blood supply vary widely. Over seven million people who originated from countries where Chagas' disease is endemic reside in the United States, and it is estimated that over 100,000 people are asymptomatically infected with T. cruzi in the United States and Canada (8, 20) . Screening of blood donors in Los Angeles County (California) has demonstrated T. cruzi seropositivity rates of 1 in 500 (22) . However, screening of 100,019 blood donors in the southwestern United States identified only three donors who were repeatedly seropositive (10) . In addition, look-back studies of 11,430 cardiac surgery patients who received massive transfusions in the United States and Canada failed to demonstrate transmission of T. cruzi (12) , yet transmission of T. cruzi via infected blood products does occur in the United States and Canada; at least six cases of transmission of T. cruzi infection by blood product transfusion have been documented (5, 7, 24) . Clearly, treating blood products with the photochemical treatment process could reduce, if not eliminate, this risk.
Gentian violet treatment of blood products to inactivate T. cruzi has been used in endemic areas since the 1950s (16) . This process is poorly accepted by patients because of discoloration of the skin and because of its uncertain safety. In addition, gentian violet may not inactivate other agents that contaminate transfused blood. Other pathogen inactivation systems under evaluation for platelet concentrates and plasma include dimethylene blue and light (23, 26) , riboflavin and light (24) , and an ethylene amine derivative (V.I. Technologies, Inc., Watertown, Mass.) (4). In addition, methods for inactivating pathogens in packed red blood cells are under development. These include S-303 (Cerus Corporation) and dimethylene blue and Inactine (24) . A recent presentation suggested that T. cruzi was inactivated by an ethylene amine derivative treatment of contaminated red blood cells (17) .
In this publication, we have demonstrated that amotosalen and UVA photochemical treatment effectively inactivates high levels of T. cruzi in contaminated plasma and platelet concentrates to below the level of detection, Ͼ5.0 log 10 TCID 50 /ml for plasma and Ͼ5.4 log 10 TCID 50 /ml for platelets. This suggests that amotosalen and UVA photochemical treatment will prevent transfusion-associated T. cruzi infection in addition to providing protection from other viral and bacterial transfusionassociated infections.
